Innovent Biologics, a China-based biopharmaceutical company, announced that its new drug application for its proposed adalimumab biosimilar IBI303, referencing Humira, was accepted by the National Medical Products Administration.
Earlier this week, Innovent Biologics, a China-based biopharmaceutical company, announced that its new drug application for its proposed adalimumab biosimilar IBI303, referencing Humira, was accepted by the National Medical Products Administration (NMPA, formerly known as the China Food and Drug Administration).
The application was accepted based on analytical, clinical, and pharmacokinetic (PK) data generated by 3 clinical studies. Innovent is seeking indications for the treatment of ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Phase 3 comparative efficacy and safety studies were conducted in patients with ankylosing spondylitis. In addition, researchers also analyzed and compared PK parameters and immunogenicity of IBI303 versus reference adalimumab.
“Innovent successfully developed IBI303, which will provide as an alternative to the branded original product. Because of the high price of the branded drug, many patients in China have difficulty getting treatment for these chronic disease[s] which require long-term medication,” said Qinwei Zhou, MD, chief operating officer at Innovent. “We believe IBI303 will become a high-quality biosimilar drug for Chinese patients.”
Michael Yu, the founder, CEO, and chairman of Innovent explained that IBI303 is the second new drug application that the company has submitted to the NMPA. Within its pipeline, Innovent has 2 other potential biosimilars currently undergoing phase 3 clinical trials: IBI301, a proposed biosimilar rituximab, and IBI305, a proposed biosimilar bevacizumab.
“We are excited about reaching this important milestone much quicker than we originally planned. Our team will continue to deliver high-quality biopharmaceutical drug[s] from our rich pipeline to benefit more ordinary people,” said Yu.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.